Last reviewed · How we verify
PD-1 Inhibitor + Chemotherapy
This combination therapy blocks PD-1 immune checkpoints to restore anti-tumor immunity while chemotherapy directly kills cancer cells.
This combination therapy blocks PD-1 immune checkpoints to restore anti-tumor immunity while chemotherapy directly kills cancer cells. Used for Advanced or metastatic solid tumors (specific indication not publicly detailed).
At a glance
| Generic name | PD-1 Inhibitor + Chemotherapy |
|---|---|
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Drug class | PD-1 inhibitor + chemotherapy combination |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The PD-1 inhibitor removes the brakes on T-cell mediated immune responses by blocking the PD-1/PD-L1 pathway, allowing the immune system to recognize and attack cancer cells. Concurrent chemotherapy provides direct cytotoxic effects against tumor cells and can enhance immunogenicity. The synergistic approach aims to improve response rates and survival compared to either agent alone.
Approved indications
- Advanced or metastatic solid tumors (specific indication not publicly detailed)
Common side effects
- Fatigue
- Nausea and vomiting
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Myelosuppression
- Diarrhea
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (PHASE3)
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (PHASE1, PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: